

Datasheet

Anti-Follistatin Clone 17/2

Product Name	Anti Human Follistatin 288 17/2
Catalogue Number	17/2
Clone, Isotype	17/2, IgG1
Format	IgG
Tested Applications	WB, IHC-P, ELISA, ICC

Description:

Follistatin is a single-chain glycosylated protein that inhibits follicle stimulating hormone (FSH) release. Alternative splicing of Follistatin mRNA yields two isoforms, FS315 and FS288. FS288 is the main cell-surface form and binds to surface heparin sulphate proteoglycans. Clone 17/2 recognizes recombinant human Follistatin 288, allowing for detection of FSH levels using various analysis methods. This antibody also works in a two site ELISA with Clone 29/9.

Product Details:

Form in stock: IgG Purified – 1.0 mg/mL. Also available as unpurified supernatant.

Host: Mouse

Specificity: Recognizes human Follistatin isoform FS288, raised against recombinant human FS288.

Human Histology positive control: Testis

Fusion partner: Spleen cells immunised from immunised Balb/c mice were fused with cells of the SP2/0 myeloma cell line.


Storage: Store at +4°C or -20°C. Avoid repeated freezing and thawing.

Shelf life: 18 months from date of dispatch.

Regulatory/ Restrictions: For research and commercial purposes.

Applications	Suggested Dilution
Western Blot	1 µg/mL ¹
Immunohistochemistry - Paraffin	10 µg/mL ¹
ELISA	1 µg/mL ³
Immunocytochemistry	70 µg/mL ²


Applications:



Clone 17/2 used to detect immunoreactivity with FS288 by IHC-P

Image caption: Immunolocalization of FS315 and FS288 to PC3 and LNCaP cell lines. Positive immunoreactivity for FS315 localized to the cytoplasm of the epithelial tumor cell lines LNCaP (A) and PC3 (B) using H10 antibody, no immunoreactivity was present if the antibody was preabsorbed with FS315 peptide (*inset A, inset B*). Mouse IgG antibody controls were negative (*inset C, inset D*). (McPherson, S.J. et al. 1999)


Concentration used: 10 µg/mL



Western Blots showing binding of 17/2 to isoforms of FS288

Image Caption: A. Protein bands corresponding to the approximate 31 and 35K molecular weight isoforms of FS were detected in PC3 media (lane 2) and lanes containing hrFS288 protein (lane 1). (McPherson, S.J. et al. 1999)


Concentration used: 1 µg/mL



Clone 17/2 used to detect FS288 expression in fetal and adult Leydig cells by ICC

Image caption: Follistatin immunoreactivity was first detectable immediately after birth in the fetal generation of Leydig cells (a, day 7, *arrows*) and immunostaining was equally intense in the adult generation of Leydig cells when they appeared (b, day 27) and remained intense to adulthood (not shown). (Majdic, G et al.)

Concentration used: 70 µg/mL



Antibody 17/2 used to detect Fst levels using two-site ELISA with antibody 29/9

Image caption: Dose-response curves for various human biological fluid samples containing follistatin using the optimized ELISA procedure. (Evans, L et al.)

Dilution used: 1 µg/mL

References:

1. McPherson, S., Mellor, S., Wang, H., Evans, L.W., Groome, N.P., Risbridger, G.P. (1999) Expression of Activin A and Follistatin Core Proteins by Human Prostate Tumor Cell Lines. *Endocrinology*; 140 (11): 5303-5309.
2. Majdic, G., McNeilly, A.S., Sharpe, R.M., Evans, L.R., Groome, N.P., Saunders P.T.K. (1997) Testicular Expression of Inhibin and Activin Subunits and Follistatin in the Rat and Human Fetus and Neonate and During Postnatal Development in the Rat. *Endocrinology*; 138 (5): 2136-2147.
3. Evans, L.W., Muttukrishna, S., Groome, N.P. (1998) Development, validation and application of an ultra-sensitive two-site enzyme immunoassay for human Follistatin. *Journal of Endocrinology*; 156 (2) 275-282.
4. Fitzgerald, A. M., Benz, C., Clark, A. F., Wordinger, R. J. (2012). The Effects of Transforming Growth Factor-β2 on the Expression of Follistatin and Activin A in Normal and Glaucomatous Human Trabecular Meshwork Cells and Tissues. *Investigative Ophthalmology & Visual Science*, 53(11), 7358-7369. **IHC, Dilution used 1:100**
5. Hands, J.R., Abel, P., Ashton, K. et al. *Anal Bioanal Chem* (2013) 405: 7347. **IHC-P, Dilution used 1:500**
6. Mabuchi, Y., Yamoto, M., Minami, S., Umesaki, N. (2006) Immunohistochemical localization of inhibin and activin subunits, activin receptors, and Smads in ovarian clear cell adenocarcinoma. *Oncology Reports* 15.2; 291-296. **IHC-P, Dilution used 70 µg/mL**